药物发现解决方案。公司主要向生物技术与制药公司提供药物发现解决方案以于公司向客户提供研究结果时换取服务费。如若日后公司的合作项目达到特定的里程碑或发生相关合约规定的事件(例如在特定地区成功商业化)，公司亦预期获得额外的特许权使用费、里程碑或者或有付款。QUANTUMPH-P (02228) releases its interim results for the six months ending June 30, 2024...
QUANTUMPH-P (02228) releases its interim results for the six months ending June 30, 2024. The group's revenue is 0.103 billion RMB, a year-on-year growth of 28.34%; shareholders' attributable loss is 1.237 billion RMB; loss per share is 1.7 RMB.
The company is a leading global innovative research and development platform based on quantum physics, empowered by artificial intelligence and driven by robotics. The company combines quantum physics-based first-principle calculations, advanced artificial intelligence, high-performance cloud computing, and scalable and standardized robotic automation to provide pharmaceutical and materials science research and development solutions and services to global conglomerates and innovative companies in industries such as pharmaceuticals and materials science, including agriculture technology, energy and new chemicals, and cosmetics. In the six months ending June 30, 2024, the company's revenue comes from providing drug discovery solutions and smart automation solutions.
Drug discovery solutions. The company primarily provides drug discovery solutions to biotechnology and pharmaceutical companies in exchange for service fees when delivering research results to customers. If future collaboration projects of the company achieve specific milestones or events as stipulated in relevant contracts (such as successful commercialization in specific regions), the company also expects to receive additional royalties, milestones, or contingent payments.
Smart automation solutions. The company's smart automation solutions mainly include solid-state development services and automated chemical synthesis services. The company generates revenue from smart automation solutions primarily in the form of service fees.